Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 353

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Phase II Multicenter Study of Bendamustine Plus Rituximab in Patients With Relapsed Indolent B-Cell and Mantle Cell Non-Hodgkin's Lymphoma

Robinson, K. Sue, Williams, Michael E., van der Jagt, Richard H., Cohen, Philip, Herst, Jordan A., Tulpule, Anil, Schwartzberg, Lee S., Lemieux, Bernard, Cheson, Bruce D.·2008·Journal of Clinical Oncology
DOI 10.1200/jco.2008.17.0001
Open this paper in CoChat — free account

Abstract

Purpose: Bendamustine HCl is a bifunctional mechlorethamine derivative with clinical activity in the treatment of non-Hodgkin's lymphoma. This study evaluated bendamustine plus rituximab in 67 adults with relapsed, indolent B-cell or mantle cell lymphoma without documented resistance to prior rituximab. Patients and Methods: Patients received rituximab 375 mg/m 2 intravenously on day 1 and bendamustine 90 mg/m 2 intravenously on days 2 and 3 of each 28-day cycle for four to six cycles. An additional dose of rituximab was administered 1 week before the first cycle and 4 weeks after the last cycle. Sixty-six patients (median age, 60 years) received at least one dose of both drugs. Results: Overall response rate was 92% (41% complete response, 14% unconfirmed complete response, and 38% partial response). Median duration of response was 21 months (95% CI, 18 to 24 months). Median progression-free survival time was 23 months (95% CI, 20 to 26 months). Outcomes were similar for patients with indolent or mantle cell histologies. The combination was generally well tolerated; the primary toxicity was myelosuppression (grade 3 or 4 neutropenia, 36%; grade 3 or 4 thrombocytopenia, 9%). Conclusion: Bendamustine plus rituximab is an active combination in patients with relapsed indolent and mantle cell lymphoma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2008.17.0001

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 353

Metadata

Authors
Robinson, K. S., Williams, M. E., van der Jagt, R. H., Cohen, P., Herst, J. A., Tulpule, A., Schwartzberg, L. S., Lemieux, B., & Cheson, B. D.
Venue
Journal of Clinical Oncology
Publisher
American Society of Clinical Oncology (ASCO)
Published
2008-09-20
Volume
26
Issue
27
Pages
4473-4479
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
DOI
10.1200/jco.2008.17.0001
OpenAlex
W2120755425
Cited by
353
References
19
FWCI
22.12
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase II Multicenter Study of Bendamustine Plus Rituximab in Patients With Relapsed Indolent B-Cell and Mantle Cell Non-Hodgkin's Lymphoma. https://app.cochat.ai/papers/10.1200/jco.2008.17.0001
The paper
Robinson, K. S., Williams, M. E., van der Jagt, R. H., Cohen, P., Herst, J. A., Tulpule, A., Schwartzberg, L. S., Lemieux, B., & Cheson, B. D. (2008). Phase II Multicenter Study of Bendamustine Plus Rituximab in Patients With Relapsed Indolent B-Cell and Mantle Cell Non-Hodgkin's Lymphoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2008.17.0001

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.